Tosk Inc. is a biopharmaceutical company focused on improving outcomes for cancer patients. The company develops new drugs aimed at enhancing the safety and efficacy of existing cancer therapies while blocking the activity of cancer genes. Tosk's proprietary methods are designed to selectively prevent the adverse side effects of current treatments without compromising their effectiveness.

Tosk serves the oncology market, targeting patients undergoing cancer treatments who are affected by the side effects of these therapies. The company's business model revolves around drug discovery and development, with revenue generated through the commercialization of its proprietary drugs, partnerships, and licensing agreements.

Tosk operates in the biopharmaceutical sector, leveraging cutting-edge research and development to address unmet medical needs in oncology.

Keywords: biopharmaceutical, oncology, cancer therapy, drug development, gene blocking, side effects, proprietary methods, patient outcomes, safety, efficacy.